EUCTR2015-005766-39-NLActive, not recruitingPhase 1
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kd Inhibitor, GS-9820
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Gilead Sciences, Inc.
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1) Receiving GS-9820 in Study GS-US-315-0102 with objective evidence of clinical benefit defined as at least stable disease on imaging assessed by the IRC at the time of Study GS-US-315-0102 closure
- •2) For female subjects of childbearing potential, willingness to use a protocol recommended method of contraception during heterosexual intercourse from the signing of informed consent throughout the study treatment period and up to 30 days from the last dose of idelalisib
- •3) For male subjects of reproductive potential having intercourse with females of childbearing potential, willing to use a protocol recommended method of contraception during heterosexual intercourse and to refrain from sperm donation throughout the study treatment period and for 90 days following discontinuation of idelalisib
- •4) Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions, including mandatory prophylaxis for Pneumocystis jirovecci pneumonia (PJP). Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.
- •5) Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, possible side effects, potential risks and discomforts, and other pertinent aspects of study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
Exclusion Criteria
- •1) Known hypersensitivity or intolerance to any of the active substances or excipients in the formulation of idelalisib.
- •2) Toxicities that would preclude initiating therapy with idelalisib prior to enrolment (eg history of drug-induced pneumonitis, ongoing inflammatory bowel disease)
- •3) Concurrent participation in another therapeutic clinical trial.
- •4) Pregnant or breastfeeding.
- •5) Ongoing infection, treatment, or prophylaxis for CMV within the past 28 days.
Investigators
Similar Trials
Completed
Phase 4
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3K* Inhibitor, GS-9820Chronic Lymphatic Leukemia10024324CLLNL-OMON43418Gilead Sciences6
Active, not recruiting
Phase 1
WN41874 - Gantenerumab Open Label Extension StudyAlzheimer's disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852EUCTR2019-004431-23-GBF Hoffmann-La Roche Ltd168
Not yet recruiting
Phase 4
A clinical trial to evaluate the efficacy and safety of FDC of Azelnidipine and Telmisartan ascompared to FDC of Amlodipine and Telmisartan in Indian Essential Hypertensive PatientsCTRI/2023/07/055818Dr Akshay Ashok Bafna
Active, not recruiting
Phase 1
A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic Pain. This will be followed by a randomised withdrawal phase (Part B) for a subset of patients.europathic painEUCTR2004-004395-36-GBGW Pharma Ltd383
Not yet recruiting
Phase 3
A clinical trial to study the effects of Zenotechs Etanercept 50 mg injection in comparison with Wyeth?s Enbrel® injection in patients with moderate to severe rheumatoid arthritis with inadequate response to methotrexateCTRI/2011/05/001724Zenotech Laboratories Ltd110